Skip to main content
SpringerLink
Log in

Introduction of biosimilar DMARDs cost saving to UK NHS

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. National Health Service

  2. British pounds

Reference

  • Aladul MI, et al. Impact of Infliximab and Etanercept Biosimilars on Biological Disease-Modifying Antirheumatic Drugs Utilisation and NHS Budget in the UK. BioDrugs : 10 Nov 2017. Available from: URL: http://doi.org/10.1007/s40259-017-0252-3

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Introduction of biosimilar DMARDs cost saving to UK NHS. PharmacoEcon Outcomes News 792, 14 (2017). https://doi.org/10.1007/s40274-017-4537-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-017-4537-z

Search

Navigation